Summary Glucagon-like peptide-1 (GLP-1) receptor agonists areincretinanalogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity.
Theincretinhormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) play central roles in metabolic and cardiovascular regulation.GLP-1receptor agonists (GLP-1RAs) are established therapies for type 2 diabetes mellitus (T2DM) and obesity because of their insulinotropiceffects, weight reduction, and proven cardiovascular benefit in trial level. In ...
Both the GIGD and theincretineffectdepend on the amount of glucose ingested: for higher doses the GIGD may amount to 80%, which shows that thiseffectis a major contributor to glucose tolerance. The main mechanism behind it is stimulation of insulin secretion by a proportional secretion of the insulinotropic hormones GIP andGLP-1.
1. Introduction: TheIncretinEffectTo understandGLP-1agonists, one must first understand the "IncretinEffect." This physiological phenomenon describes the observation that oral glucose administration elicits a much higher insulin response than an…
Notably, the glucoregulatory and anorectic activities of GIP andGLP-1have supported development ofincretin-based therapies for the treatment of type 2 diabetes and obesity. Here we review evolving concepts ofincretinaction, focusing predominantly onGLP-1, from discovery, to clinical proof of concept, to therapeutic outcomes.
Moving forward, it's essential to keep these visual contexts in mind when discussing Incretin Effect Of Glp-1.
GLP-1— glucagon-like peptide-1 — is anincretinhormone. TheGLP-1receptor agonist drug class mimics it pharmacologically. This article coversGLP-1hormone biology, how the drug class works, what's FDA-approved as of April 2026, and theGLP-1pathway genetics including GLP1R, FTO, and MC4R.
